Analysis of Key Genes and miRNA-mRNA Networks Associated with Glucocorticoids Treatment in Chronic Obstructive Pulmonary Disease
Jian-Jun Wu,Ping-An Zhang,Ming-Zhe Chen,Yi Zhang,Wei-Sha Du,Xiao-Ning Li,Guo-Chao Ji,Liang-Duo Jiang,Yang Jiao,Xin Li
DOI: https://doi.org/10.2147/copd.s441716
2024-02-29
International Journal of COPD
Abstract:Jian-Jun Wu, 1 Ping-An Zhang, 1 Ming-Zhe Chen, 2 Yi Zhang, 1 Wei-Sha Du, 1 Xiao-Ning Li, 1 Guo-Chao Ji, 1 Liang-Duo Jiang, 3 Yang Jiao, 4, &ast Xin Li 5, &ast 1 Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 2 Infectious Disease Department, Henan Provincial Hospital of Traditional Chinese Medicine, Zhengzhou, Henan, People's Republic of China; 3 Respiratory Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 4 Respiratory Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 5 Glaucoma Department, Eye Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xin Li, Glaucoma Department, Eye Hospital, China academy of Chinese Medical Sciences, Beijing, People's Republic of China, Email Background: Some patients with chronic obstructive pulmonary disease (COPD) benefit from glucocorticoid (GC) treatment, but its mechanism is unclear. Objective: With the help of the Gene Expression Omnibus (GEO) database, the key genes and miRNA-mRNA related to the treatment of COPD by GCs were discussed, and the potential mechanism was explained. Methods: The miRNA microarray dataset (GSE76774) and mRNA microarray dataset (GSE36221) were downloaded, and differential expression analysis were performed. Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the differentially expressed genes (DEGs). The protein interaction network of the DEGs in the regulatory network was constructed with the STRING database, and the key genes were screened through Cytoscape. Potential downstream target genes regulated by differentially expressed miRNAs (DEMs) were predicted by the miRWalk3.0 database, and miRNA-mRNA regulatory networks were constructed. Finally, some research results were validated. Results: 1 Four DEMs and 83 DEGs were screened; 2 GO and KEGG enrichment analysis mainly focused on the PI3K/Akt signalling pathway, ECM receptor interaction, etc.; 3 CD2, SLAMF7, etc. may be the key targets of GC in the treatment of COPD; 4 18 intersection genes were predicted by the mirwalk 3.0 database, and 9 pairs of miRNA-mRNA regulatory networks were identified; 5 The expression of miR-320d-2 and TFCP2L1 were upregulated by dexamethasone in the COPD cell model, while the expression of miR-181a-2-3p and SLAMF7 were downregulated. Conclusion: In COPD, GC may mediate the expression of the PI3K/Akt signalling pathway through miR-181a-2-3p, miR-320d-2, miR-650, and miR-155-5p, targeting its downstream signal factors. The research results provide new ideas for RNA therapy strategies of COPD, and also lay a foundation for further research. Keywords: COPD, GC, GEO database, miRNA-mRNA, DEMs, DEGs Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airway that is characterized by chronic inflammation of the airway, lung parenchyma, and pulmonary vessels. Alveolar macrophages, T lymphocytes (especially CD8+), and neutrophils are increased in different parts of the lung, and eosinophils are increased in some patients. 1 Among the drugs for the treatment of chronic airway inflammatory diseases, glucocorticoids (GCs) are recognized as the most rapid and potent anti-inflammatory drugs. They have achieved good clinical efficacy in the treatment of bronchial asthma 2,3 and COPD. 4–11 In patients with moderate to severe acute exacerbation of COPD (AECOPD), systemic use of GCs improves forced expiratory volume in one second (FEV 1 ) and oxygenation status and shortens rehabilitation and hospitalization time. 12 Compared with systemic GCs, inhaled corticosteroids (ICSs) have fewer adverse reactions and can replace or partially replace systemic GCs. 13–15 However, some studies have shown that patients with COPD do not benefit from inhaled corticosteroid (ICS) therapy alone. Specifically, ICS treatment cannot effectively delay the long-term decline in FEV 1 or reduce the mortality of patients with COPD. 16,17 GCs resistance caused by HDAC2 activity decreases, dysfunction of corticosteroid glucocorticoid receptor-α and GR-β increases in epithelial cells, etc., may be a reason why COPD patients cannot benefit from GC treatment. 18–20 Recent studies have shown that microRNAs are associated wit -Abstract Truncated-
respiratory system